U.S. markets closed

Minerva Neurosciences, Inc. (NERV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2900+0.0800 (+2.49%)
At close: 4:00PM EDT

Minerva Neurosciences, Inc.

1601 Trapelo Road
Suite 286
Waltham, MA 02451
United States
617 600 7373

Full Time Employees13

Key Executives

NameTitlePayExercisedYear Born
Dr. Rémy LuthringerExec. Chairman & CEO736.03kN/A1961
Mr. Geoffrey Robin RaceExec. VP, CFO & Chief Bus. Officer516.84kN/A1961
Mr. Joseph ReillySr. VP & COON/AN/A1975
Mr. Frederick W. AhlholmSr. VP & Chief Accounting OfficerN/AN/A1966
Mr. William B. BoniVP of Investor Relations & Corp. CommunicationsN/AN/A1952
Mr. Devin Whittemore SmithSr. VP, Gen. Counsel & Sec.N/AN/A1968
Dr. Michael DavidsonChief Medical OfficerN/AN/A1950
Dr. Jay B. Saoud Ph.D.Sr. VP and Head of R&DN/AN/A1959
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Corporate Governance

Minerva Neurosciences, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.